In this 5 for 5 Hot Topics, Phillip Koo, MD. presents the clinical background of Axumin™ (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer, the first FDA-approved F18 PET Imaging Agent indicated in for use in patients with suspected recurrent prostate cancer.  Dr. Koo discusses its use for men with suspected prostate cancer recurrence based on elevated PSA levels following prior treatment. The product's safety, efficacy, and good inter-reader variability, as well as the adverse reactions including injection site pain, redness, and a metallic taste in the mouth.

Biography:

Phillip Koo, MD
 

For More information of F18:

Read about the FDA Approval of Axumin™

Read More on Fluciclovine F 18: Clin Nucl Med. 2015 Aug;40(8):e386-91. doi: 10.1097/RLU.0000000000000849.